The first case of Streptococcus intermedius brain abscess with hemophagocytic histiocytosis

Jia Zhang1,2,3, Jianjun Wang1,2,3, Jing Gan1,2,3

  • 1Department of Pediatrics, West China Second University Hospital, Sichuan University, No. 20, Section Three, South Renmin Road, Chengdu, 610041, China.

Abstract

Insights

This case report highlights Streptococcus intermedius meningitis as a cause of hemophagocytic lymphohistiocytosis (HLH). Early diagnosis via bone marrow biopsy and advanced sequencing are crucial for managing this rare bacterial infection-associated HLH.

Area of Science:

  • Pediatric Infectious Diseases
  • Immunology
  • Neurology

Background:

  • Hemophagocytic lymphohistiocytosis (HLH) is a severe immune dysregulation, often triggered by infections.
  • While viral triggers are common, bacterial causes of HLH are less frequently reported.
  • This study details the first reported case of HLH secondary to Streptococcus intermedius meningitis.

Observation:

  • An 11-year-old boy presented with fever, headache, and vomiting, progressing to cerebritis and brain abscess.
  • Cerebrospinal fluid analysis was initially negative, but metagenomics next-generation sequencing (mNGS) identified Streptococcus intermedius.
  • The patient developed recurrent fever with Kawasaki disease-like symptoms, followed by cytopenias and bone marrow findings consistent with HLH.

Findings:

  • Metagenomics next-generation sequencing (mNGS) proved vital in identifying the pathogen when conventional tests failed.
  • Early bone marrow biopsy confirmed hemophagocytic lymphohistiocytosis (HLH), establishing infection-associated HLH (IAHS).
  • Successful treatment involved antibiotics, high-dose immunoglobulin, and methylprednisolone, without conventional chemotherapy.

Implications:

  • This case expands the spectrum of bacterial pathogens causing HLH, emphasizing Streptococcus intermedius.
  • It underscores the diagnostic utility of mNGS for identifying pathogens in complex infections.
  • Effective management of IAHS may involve high-dose glucocorticoids and immunoglobulins, potentially avoiding traditional chemotherapy.